[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2000078299A3 - Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy - Google Patents

Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy Download PDF

Info

Publication number
WO2000078299A3
WO2000078299A3 PCT/US2000/005186 US0005186W WO0078299A3 WO 2000078299 A3 WO2000078299 A3 WO 2000078299A3 US 0005186 W US0005186 W US 0005186W WO 0078299 A3 WO0078299 A3 WO 0078299A3
Authority
WO
WIPO (PCT)
Prior art keywords
severity
preventing
reducing
composition
side effects
Prior art date
Application number
PCT/US2000/005186
Other languages
French (fr)
Other versions
WO2000078299A2 (en
Inventor
Stephen Thomas Davis
Original Assignee
Glaxo Group Ltd
Stephen Thomas Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Stephen Thomas Davis filed Critical Glaxo Group Ltd
Priority to AU79811/00A priority Critical patent/AU7981100A/en
Priority to EP00970426A priority patent/EP1177016A2/en
Priority to JP2001504363A priority patent/JP2003502362A/en
Priority to US09/914,392 priority patent/US6620818B1/en
Publication of WO2000078299A2 publication Critical patent/WO2000078299A2/en
Publication of WO2000078299A3 publication Critical patent/WO2000078299A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition and method for preventing/reducing the severity of epithelial cytotoxicity side effects, such as alopecia, plantar-palmar syndrome and/or mucositis, in a subject receiving chemotherapy and/or radiation therapy, wherein an effective amount of a cyclin-dependent kinase II inhibitor is contemporaneously administered to the patient.
PCT/US2000/005186 1999-03-04 2000-03-01 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy WO2000078299A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU79811/00A AU7981100A (en) 1999-03-04 2000-03-01 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
EP00970426A EP1177016A2 (en) 1999-03-04 2000-03-01 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
JP2001504363A JP2003502362A (en) 1999-03-04 2000-03-01 Compositions and methods for preventing / reducing the severity of side effects of chemotherapy and / or radiation therapy
US09/914,392 US6620818B1 (en) 2000-03-01 2000-03-01 Method for reducing the severity of side effects of chemotherapy and/or radiation therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9904932.2A GB9904932D0 (en) 1999-03-04 1999-03-04 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904932.2 1999-03-04

Publications (2)

Publication Number Publication Date
WO2000078299A2 WO2000078299A2 (en) 2000-12-28
WO2000078299A3 true WO2000078299A3 (en) 2001-10-18

Family

ID=10848914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005186 WO2000078299A2 (en) 1999-03-04 2000-03-01 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy

Country Status (5)

Country Link
EP (1) EP1177016A2 (en)
JP (1) JP2003502362A (en)
AU (1) AU7981100A (en)
GB (1) GB9904932D0 (en)
WO (1) WO2000078299A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU2001229727B2 (en) 2000-02-07 2004-10-14 Bristol-Myers Squibb Co. 3-aminopyrazole inhibitors of cyclin dependent kinases
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
ATE418333T1 (en) * 2002-11-06 2009-01-15 Cyclacel Ltd COMBINATION OF DOCETAXEL AND A CDK INHIBITOR
WO2007044698A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
SI2074122T1 (en) 2006-09-15 2011-10-28 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
KR101432171B1 (en) 2013-01-22 2014-08-22 한국원자력의학원 Composition for diagnosis of radio-resistance or radio-sensitive CDK11A marker and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012506A1 (en) * 1994-10-24 1996-05-02 Baylor College Of Medecine Senescent cell-derived inhibitors of dna synthesis
WO1997027297A1 (en) * 1996-01-23 1997-07-31 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1999010325A1 (en) * 1997-08-06 1999-03-04 Glaxo Group Limited Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
WO1999052869A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012506A1 (en) * 1994-10-24 1996-05-02 Baylor College Of Medecine Senescent cell-derived inhibitors of dna synthesis
WO1997027297A1 (en) * 1996-01-23 1997-07-31 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1999010325A1 (en) * 1997-08-06 1999-03-04 Glaxo Group Limited Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
WO1999052869A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes

Also Published As

Publication number Publication date
WO2000078299A2 (en) 2000-12-28
EP1177016A2 (en) 2002-02-06
GB9904932D0 (en) 1999-04-28
JP2003502362A (en) 2003-01-21
AU7981100A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
WO2000056296A3 (en) Compositions for improving fertility
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
WO2001027109A3 (en) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives
AU1211302A (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
NZ241210A (en) 16alpha,17alpha-butylidenedioxy-11b, 21-dihydroxypregn-4-ene-3,20-dione derivatives substituted in either or both the 6alpha- and 9alpha- positions by fluorine; pharmaceutical compositions, methods of preparation and treatment
WO2001062235A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
TR199903141T2 (en) CD154 blockade therapy for therapeutic protein blocker syndrome.
WO2000078299A3 (en) Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
HUP0301506A3 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
WO2002022145A3 (en) Components of canola for the treatment of cancer
WO2002074036A3 (en) Substituted benzopyranones as telomerase inhibitors
GB9521608D0 (en) Pharmaceutical composition
WO2001057042A3 (en) 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
HK1028190A1 (en) Compositions and articles for reducing the effectsof inflammation.
WO2000052013A3 (en) Thiazoloindolinone compounds
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2002062334A3 (en) Cancer chemopreventative compounds and compositions and methods of treating cancers
EP0161816A3 (en) Urogastrone
EP0443028A4 (en) Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer.
IL127851A0 (en) Inhibition of TNF activity
AU2002212489A1 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
MY133682A (en) Substituted pyrroles
NO20010979D0 (en) Procedure for Relieving the Adverse Effects of Interleukin-2
EG20082A (en) Process for preparing of octadecyl-(2-N-methylpiperidino)-ethyl-phosphate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09914392

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000970426

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 504363

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000970426

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2000970426

Country of ref document: EP